March 13th Options Now Available For Humana (HUM)

Humana (HUM) is the subject of options trade ideas: a $190 put is bidding $8.00 (article states a resulting cost basis of $182.00) and is ~3% OTM versus the $194.90 share price, with a 60% modeled chance to expire worthless and a 4.21% one-period (35.78% annualized) yield if it does. On the call side, a $200 covered call bids $9.70, is ~3% OTM, carries a 51% chance to expire worthless, would produce a 7.59% total return if called at the March 13 expiration and a 4.98% (42.29% annualized) premium boost if it expires worthless; implied vols are ~55% (put) and 57% (call) versus a trailing 12‑month volatility of 50%.

Analysis

Market structure: Short-dated option sellers and income-focused retail/RIAs directly benefit from the quoted yields — selling the Mar-13 $190 put collects $8 (net basis $182 vs spot $194.90) and implied odds show ~60% chance of expiring worthless; brokers and market-makers capture flow/bid-ask. Issuer-level competitive dynamics for HUM are largely unchanged by this options flow, but concentrated option selling can mechanically compress intraday liquidity and increase gamma-driven moves around key news; implied vols (55–57%) sit ~5–7 percentage points above realized 50%, signaling mild option-rich pricing.

Risk assessment: Tail risks include adverse CMS Medicare Advantage rate changes, litigation or material miss in upcoming earnings — any one could flip a modest assignment into 10–30% downside in weeks. Timeframes: immediate (days) risk is assignment/gamma into March 13 expiry; short-term (weeks) IV re-pricing around earnings/CMS decisions; longer-term secular profit pressure from policy shifts over quarters/years. Hidden dependencies include broker early assignment risk, capital tie-up if put is assigned, and IV collapse after benign news which would hurt new sellers.

Trade implications: Direct actionable plays are income strategies sized conservatively (cash-secured puts, covered calls) given high implied vol and event risk; prefer defined-risk structures (put spreads, collars) where max loss is capped. If you want directional, prefer buying stock funded by selling calls (covered call) only if willing to cap upside to $200 (~7.6% to expiry) and roll monthly; consider buying back/re-hedging if IV jumps >10 pts or price moves >7% intraday. Cross-asset: limited bond/FX impact, but a sector re-rate in insurers would increase correlation with long-duration assets.

Contrarian angle: Consensus treats these yields as low-risk alpha, but IV premium is modest — downside tail risk (policy or earnings shock) is likely underpriced by 5–15% probability bands. Historical parallels (MA rate shocks) show insurer equities can gap 15–25% on policy rulings; therefore pure naked put selling is likely underdone risk-taking. A preferable mispricing play is selling premium with capped risk (put spreads) or harvesting yield via covered calls rather than naked assignment exposure.

Key Decisions for Investors

• Sell-to-open HUM Mar-13 2026 $190 cash-secured put at $8 if comfortable owning shares at $182; size 1–2% of portfolio net exposure, margin cash held = $190*contracts*100, and close/roll if HUM trades < $180 or IV increases >10 pts.
• If you prefer defined risk, sell the $190/$170 Mar-13 put spread receiving ~?$ (collect net premium), which caps max loss to ~$10 per share and limits assignment risk; target max delta portfolio exposure of 2%.
• If already long HUM, sell Mar-13 $200 covered calls at $9.70 to lock ~7.6% to expiry (42% annualized); plan to roll up or buy back if HUM >$205 or IV falls >5 pts — size 2–4% of equity sleeve.
• Establish a hedged directional stance around catalyst windows: buy HUM equity and simultaneously buy a protective Mar-13 $180 put if you are >3% position size; exit/reevaluate 48hrs after earnings or CMS announcement, or if put cost falls below 1.5% of position value.